Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Launched by WESTLAKE EYE SPECIALISTS · Jun 3, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how two medications, netarsudil and brimonidine, affect eye pressure in patients with Normal Tension Glaucoma (NTG) who are already using latanoprost. The goal is to see if adding either of these medications can help lower eye pressure in patients whose pressure is currently at or below 21 mmHg, while also monitoring their visual health. The study will involve visits for assessments, including checking vision and measuring eye pressure, to see how well each medication works.

To participate in the trial, individuals need to be at least 18 years old and have been diagnosed with NTG. They should also have been using latanoprost (a common glaucoma treatment) for at least six weeks. However, certain conditions could disqualify someone, such as having other types of glaucoma or a history of severe eye surgeries. If you or a loved one are interested, this study could provide valuable information about potential new treatments for managing eye pressure in NTG.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 18 years and older
• * Diagnosed with normal tension glaucoma based on the following:
• • IOP ≤ 21mmHg
• • Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma
• • Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year
• • Open angles assessed by gonioscopy
• • Have been on latanoprost monotherapy for at least 6 weeks
• Exclusion Criteria:
• • If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.
• • Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
• • Other forms of secondary glaucoma.
• • Patients with abnormal anterior segment examination other than cataract will be excluded from the study.
• • Patients who have had incisional surgery for glaucoma (eg: MIGs).
• • Patients with refractory CME or CME persisting 3 months or more.
• • Children, cognitive impaired and critically ill subjects will not be enrolled.
• • Central Corneal Thickness (CCT) ≤ 500.
• • Prior allergy to brimonidine or netarsudil, and known to have previously failed either brimonidine or netarsudil.
• • Ocular surgery (e.g., cataract, laser, refractive) during the study or 1 year prior to entering the study.
• • The principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial.